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Purpose. To assess the brain metabolic correlates of different regional extent of ALS, evaluated 
with the King’s staging system, using brain 18F-2-fluoro-2-deoxy-D-glucose-PET (18F-FDG-PET) 
Methods. 390 ALS cases with King’s stage 1, 2, and 3 (n=390), i.e. involvement of 1, 2, and 3 
body regions respectively, underwent brain 18F-FDG-PET at diagnosis. King’s stage at PET was 
derived from ALSFRS-R and was regressed out against whole brain metabolism in the whole 
sample. The full factorial design confirmed the hypothesis that differences among groups (King’s 1, 
King’s 2, King’s 3, and 40 healthy controls - HC) existed overall. Comparisons among stages and 
between each group and HC were performed. We included age at PET and sex as covariates. 
Results. Brain metabolism was inversely correlated with stage in medial frontal gyrus bilaterally, 
and right precentral and postcentral gyri. The full factorial design resulted in a significant main 
effect of groups. There was no significant difference between stages 1 and 2. Comparing stage 3 to 
stage 1+2, a significant relative hypometabolism was highlighted in the former in the left precentral 
and medial frontal gyri, and in the right medial frontal, postcentral, precentral, and middle frontal 
gyri. The comparisons between each group and HC showed the extension of frontal metabolic 
changes from stage 1 to stage 3, with the larger metabolic gap between stage 2 and 3. 
Conclusions. Our findings support the hypothesis that in ALS the propagation of 
neurodegeneration follows a corticofugal, regional ordered pattern, extending from the motor cortex 
to posterior and anterior regions.  
 







































































Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease affecting upper and lower 
motor neurons, leading to muscle weakness and wasting that progressively spreads across body 
regions. In about 50% of cases also prefrontal regions are involved, causing various degrees of 
cognitive impairment of the frontotemporal type [1]. Death usually occurs within 2-5 years due to 
respiratory failure [2]. It has been proposed that ALS pathology disseminates in a regional ordered 
sequence, following a cortico-efferent spreading model [3].  
In recent years the King’s staging system has been proposed for ALS, mainly based on the 
extension of the disease across body regions [4]. It defines the following stages: 1, symptom onset 
(involvement of the first region); 2A, diagnosis; 2B, involvement of a second region; 3, 
involvement of a third region; 4A, need for gastrostomy; 4B, need for respiratory support (non-
invasive ventilation). Central nervous system region involvement was defined by the presence of 
weakness, wasting, spasticity, dysphagia or dysarthria. Regions were defined in the same way as for 
the El Escorial criteria [5]. Afterwards, an algorithm based on ALSFRS-R has been proposed to 
estimate the King’s stages [6].  
Published data about the neuroimaging correlates of King’s stages are limited to few Magnetic 
Resonance Imaging (MRI) studies based on small samples [7–9]. The aim of this study was to 
assess the brain metabolic correlates of different regional extent of ALS, evaluated according to the 
King’s staging system, using brain 18F-2-fluoro-2-deoxy-D-glucose-PET (18F-FDG-PET), since it is 





































































Materials and Methods 
 
Study partecipants 
Patients diagnosed with definite, probable and probable laboratory-supported ALS according to El 
Escorial revised diagnostic criteria [5], who underwent brain 18F-FDG-PET at diagnosis between 
2008 and 2015 at the ALS Centre of Turin (“Rita Levi Montalcini” Department of Neuroscience, 
University of Turin, Turin, Italy) were considered eligible for the study (n=406). The present study 
includes patients whose brain 18F-FDG-PET scan was included in the analyses performed in 
previous publications. 
Forty healthy controls (HC) were included. Subjects who were referred to the PET Centre for 
suspected lung cancer but in whom no oncologic disease was detected with 18F-FDG-PET/CT and 
who had a normal neurological assessment were considered eligible as controls. Otherwise, major 
systemic illnesses, major vision disturbances, psychiatric illnesses, and diseases affecting brain 
functioning and metabolism represented exclusion criteria. 
 
Genetic Analysis 
All patients underwent genetic analysis for C9ORF72, SOD1, TARDBP, and FUS genes. All the 
coding exons and 50 bp of the flanking intron-exon boundaries of SOD1, of exon 6 of TARDBP, 
and of exons 14 and 15 of FUS have been PCR amplified, sequenced using the BigDye Terminator 
v3.1 sequencing kit (Applied Biosystems Inc.), and run on an ABIPrism 3500 genetic analyzer. 
These exons were selected as the vast majority of known pathogenic variants are known to lie 
within these mutational hotspots. A repeat-primed PCR assay was used to screen for the presence of 





































































18F-FDG-PET acquisition  
18F-FDG-PET was performed according to published guidelines [11]. Patients fasted at least six 
hours before the exam. Blood glucose was <7.2 mmol/l in all cases before the procedure. After a 
20-minute rest, about 185 MBq of 18F-FDG was injected. The acquisition started 60 minutes after 
the injection. In the patient group a whole-body scan was performed setting head-first. In the 
control group a separate brain scan was performed after the whole-body one with a time difference 
of 15 minutes. The18F-FDG-PET acquisition procedure was performed in the same environmental 
conditions in patients and controls, according to published guidelines [11]. PET/CT scans were 
performed on a Discovery ST-E System (General Electric). Brain CT (slice thickness of 3.75 
millimetres, 140 kV, 60-80 mAs) and PET scan were sequentially acquired, the former being used 
for attenuation correction of PET data. The PET images were reconstructed with 4 iterations and 28 
subsets with an initial voxel size of 2.34 x 2.34 x 2.00 mm and data were collected in 128×128 
matrices.  
 
Assessment of King’s stage 
The King’s staging is based on the spreading of motor symptoms in three different body regions 
(bulbar, upper limbs, and lower limbs), and on the use of non-invasive ventilation (NIV) and enteral 
nutrition. We used the algorithm proposed by Balendra et al. [6] to calculate King’s stage from 
ALSFRS-R. The bulbar region was considered involved if a patient lost any points on any of the 
three items regarding speech, salivation or swallowing (items 1, 2, and 3). The upper limb region 
was considered involved if a patient lost any points on either of the two items regarding handwriting 
and ability to cut food and handle utensils (items 4 and 5A). The lower limb region was considered 




































































gastrostomy was confirmed by the assessment of item 5B (evaluation of the ability to manipulate 
fastenings if a patient has a gastrostomy) rather than item 5A (answered by patients without 
gastrostomy). If a subject scored 0 points on question 10 (indicating that the patient has significant 
difficulty with dyspnoea and is considering using mechanical respiratory support) or less than 4 
points on question 12 (dropping any points on this question indicates that Bi-level Airway Pressure 
ventilation is being used), this indicated that the patient was using NIV. We classified patients 
according to the following five stages of the King’s staging system: 1, one region involved; 2, two 
regions involved; 3, three regions involved; 4A, patient needs gastrostomy; 4B, patient needs NIV.  
Since our aim was to evaluate the metabolic changes related to different regional extent of ALS, we 
focused on patients classified as King’s stages 1, 2 and 3 (n=390). Indeed, stages 1, 2, and 3 
correspond to involvement of 1, 2, and 3 body regions respectively, whereas stages 4A and 4B 




The demographic and clinical characteristics of patient groups (King’s Stage 1, 2, and 3) and HC 
were compared as follows. The χ2-test was employed for categorical variables. The Analysis of 
Variance (ANOVA) or the Kruskal-Wallis test were used for quantitative, continuous variables. The 
homogeneity assumption needed for ANOVA was evaluated through the Levene’s test. In the case 
of a significant Levene’s test, the Kruskal-Wallis test was employed instead of ANOVA.  
SPM12 implemented in Matlab R2018b (MathWorks, Natick, MA, USA) was used for image 
spatial normalization to a customized brain 18F-FDG-PET template [12]. Intensity normalization 
was performed using the 0.8 default SPM value of grey matter threshold and images were 




































































In our sample (n =390) King’s stage (1, 2, 3) was regressed out against whole brain metabolism. 
The SPM12 Multiple Regression routine was implemented with age at PET and sex as covariates 
and the height threshold was set at P<0.001 (P<0.05 FWE-corrected at cluster level). We used the 
full factorial design as implemented in SPM12 to test the hypothesis that differences among groups 
(King’s 1, King’s 2, King’s 3, HC) exist overall (i.e., main effect of groups). In case the hypothesis 
was confirmed, comparisons between groups defined according to King’s stage were performed 
through the two-sample t-test model of SPM12. For both analyses age at PET and sex were used as 
covariates and the height threshold was set at P<0.001 (P<0.05 FWE-corrected at cluster level). 
Although the scope of the study was the assessment of metabolic differences across King’s stages, 
for a more exhaustive characterization of patient metabolic state, each group defined according to 
King’s stage was compared to HC, through the two-sample t-test model of SPM12, with age at PET 
and sex as covariates, setting the height threshold at P<0.0001 (P<0.05 FWE-corrected at cluster 
level). In all the analyses only clusters containing >125 contiguous voxels were considered 
significant. Brodmann areas (BAs) were identified at a 0–2-mm range from the Talairach 





Demographic and clinical data 
Based on the ALSFRS-R at the time of PET, 165 patients (42.3%) were in King’s stage 1, 133 
(34.1%) in stage 2, and 92 (23.6%) in stage 3. Demographic and clinical characteristics of patients 
belonging to the three groups and of the whole sample are reported in Table 1. We found a 
significant difference among the three groups for site of onset (p<0.001), ALSFRS-R total score 




































































(p=0.019). However, a bivariate correlation analysis did not show any correlation between site of 
onset and King’s stage (p=0.36). Regarding the difference in ALSFRS-R total score, this could be 
expected since the King’s Stage has been calculated based on the ALSFRS-R score according to the 
algorithm published by Balendra et al. [6] As for the differences in cognitive status, these confirm a 
previous study showing that cognitive impairment in ALS tends to be more severe as the King’s 
clinical stage increases [14]. 
In the HC group the median age was 66.5 years (Interquartile Range 55.0-72.0), and the 
male/female ratio was 2.64 (29/11). In the comparisons between each stage group and HC we found 
no significant difference for age and sex distribution, with the exception of sex distribution between 




Using multiple regression analysis we found an inverse correlation between brain metabolism and 
King’s stage (with stage 3 on the relatively hypometabolic side and stage 1 on the relatively 
hypermetabolic side). We identified clusters including bilateral medial frontal gyrus (Brodmann 
Area, BA, 6), right precentral gyrus (BA 4), and right postcentral gyrus (BA 2) (Figure 1, Table 2). 
We did not identify any cluster with positive correlation. 
The full factorial design resulted in a significant main effect of groups (Supplemental Figure 1). We 
hence computed the post-hoc comparisons between the four groups. Comparing King’s stage 1 and 
King’s stage 2 groups, we did not find any significant difference. Therefore, we merged such 
groups into a King’s 1+2 group. The comparison between the King’s 1+2 group and the King’s 3 
group revealed a significant relative hypometabolism in the King’s 3 group in clusters including left 




































































and middle frontal cortex (BAs 4, 6, 3, 9, and 8) (Figure 2, Table 3). The King’s 3 group did not 
show any cluster of relative hypermetabolism as compared to the King’s 1+2 group. 
In the comparison with HC we identified two clusters of relative hypometabolism in patient groups. 
The former included occipito-temporo-parietal regions and did not show a clear pattern of extension 
along the increase of clinical stage. The latter included frontal regions and showed an extension 
from left to right emisphere from King’s stage 1 to stage 2, and a marked bilateral extension in 
stage 3 (Supplemental Figures 2, 3, and 4). No clusters of relative hypermetabolism in patient 




In this study we explored the 18F-FDG-PET correlates of ALS clinical stages according to King’s 
staging system. We focused on King’s stage 1, 2 and 3, corresponding to the spreading of motor 
impairment to 1, 2, and 3 body regions respectively. A full factorial analysis showed that group 
differences exist at global level and overlap the ones found between groups and groups and 
controls. 
In the multiple regression analysis brain metabolism negatively correlated with King’s stage. We 
found a decreasing gradient of metabolism going from King’s stage 1 to King’s stage 3 in clusters 
including right precentral and postcentral gyrus (BAs 4 and 2), and bilateral medial frontal gyrus 
(BA 6). When performing group comparisons, no significant difference was detected between 
King’s stage 1 group and King’s stage 2 group. King’s stage 3 group showed relatively 
hypometabolic clusters when compared to King’s stage 1+2 group, including left precentral and 
medial frontal gyrus (BAs 4 and 6) and right precentral, middle frontal, postcentral, and medial 




































































agreement with such findings, showing the extension of frontal metabolic changes from stage 1 to 
stage 3, with the larger metabolic gap between stage 2 and 3. Posterior clusters, including occipital 
lobes in all comparisons, of relative hypometabolism in ALS patients as compared to HC have 
already been reported [15].  
The corticospinal tracts (CST) originate from neurons mainly situated in BA 4, corresponding to the 
primary motor cortex. Nevertheless, CST fibers rise also from neurons situated in other cortical 
regions, including premotor and supplementary motor cortex (BA 6), and primary somatosensory 
cortex (BAs 1, 2, and 3). Therefore, we identified a decreasing gradient of metabolism going from 
patients with King’s stage 1 to subjects with King’s stage 3 in cortical regions from which the 
corticospinal tracts originate. Furthermore, group comparisons suggested that the main metabolic 
gap is situated between stage 2 and 3. We detected no difference between subjects with King’s 
stage 1 and 2. A possible explanation is that patients showing the involvement of three body regions 
at diagnosis subtend a more rapid neurodegenerative process, involving prefrontal cortex to a 
greater extent, as compared to patients with stage 1 and 2. Otherwise, the metabolic difference 
between stage 1 and 2 is probably under threshold, being the neurodegenerative process slower and 
less extensive.    
Clusters of relative hypometabolism in subjects with King’s stage 3 as compared to patients with 
stage 1 and 2 included BAs 4, 6 and 3 and extended towards anterior regions (BAs 8 and 9). In a 
previous study we identified a decreasing gradient of metabolism going from ALS with normal 
cognition to ALS with FTD, through cases with intermediate cognitive deficits (ALS-Ci) in frontal 
clusters including BAs 8 and 9 [16]. Synapse degeneration in BA 9 has been reported as a strong 
predictor of cognitive impairment in ALS [17]. Our findings are in agreement with 
neuropathological data suggesting that phosphorylated TDP-43 (p-TDP-43) tends to spread from 




































































staging of p-TDP-43 pathology in ALS, BAs 4 and 6 are involved in stage 1, while the extension to 
prefrontal and postcentral cortex is reported in stage 3. The data of the present study seem to 
strengthen the findings of our previous population-based cross-sectional study on cognitive 
impairment across ALS clinical stages [14], suggesting that cognitive deficits tend to be more 
severe as the clinical stage increases. In the proposed staging of pTDP-43 pathology [3] the 
neurodegenerative process was thought to spread along axonal pathways. Our results are in 
agreement with such hypothesis, that is further strengthened by several MRI studies, aimed at 
tracking the spreading of the neurodegenerative process in vivo through diffusion tensor imaging 
(DTI) [18–20], and simulation models based on brain network analyses [21,22].   
A 18F-FDG-PET study [23] on 146 patients evaluated the possible correspondence between the key 
brain regions used in the assessment of the Brettschneider’s neuropathological staging system [3], 
and metabolic patterns allowing in vivo staging of ALS. This study found that the post mortem 
neuropathological stages corresponded to distinct metabolic patterns.   
The cross-sectional design of our study may have limited our findings. Nevertheless, patients were 
tested early after diagnosis and the cognitive impairment at that time point likely reflects the speed 
of lesion spreading to non-motor cortical areas of the brain. Besides, we can assume that King’s 
stages come in succession along the disease course. Indeed, in a recent study using databases from 
two multicentre clinical trials, 725 patients were retrospectively staged through the trial course. The 
authors reported that no reversions to earlier disease stages occurred and that most people 
progressed to the consecutive stage [24]. In ALS longitudinal studies on neuroimaging are 
challenging, since disability worsens over time: patients may be unable to undergo follow up scans 
due to severe motor impairment and/or the development of respiratory failure. A recent review [25] 
evaluated published studies employing neuroimaging to track the course of ALS but did not report 




































































Another possible limitation should be considered in the interpretation of the asymmetry of the 
metabolic clusters identified in the analyses, due to the lacking of full information about 
handedness. Indeed, such data were available only for a part of the patient sample and were 
unavailable for controls. A further possible limitation is the absence of partial volume effect 
correction for cortical atrophy. Unfortunately, MRI scans were not available for all subjects. 
However, studies employing voxel-based atrophy correction of resting glucose metabolism showed 
that metabolic measurements were relatively independent of brain atrophy [26]. 
On the other hand, our study increases the knowledge about the neuroimaging correlates of King’s 
stages, which is still limited to few MRI studies with small samples. In this field, a recent study 
using magnetic resonance (MR) high angular resolution diffusion imaging (HARDI), suggested an 
early pattern of microstructural degeneration in ALS, mainly involving the CST and the corpus 
callosum [7]. Nevertheless, in such study patients with early disease stages were not compared to 
cases with more advanced stages. A further study investigated connectivity alterations associated 
with the different stages of ALS [8], employing magnetoencephalography and MRI. The authors 
suggested that modifications, in terms of increased connectedness of functional brain networks, are 
related to disease progression. These results further support the hypothesis of multi-system 
involvement of brain networks in ALS. Finally, a longitudinal study [9] reported that the King’s 
ALS disease stages estimated from the ALSFRS-R correlated with CST diffusion measures in 
C9orf72 carriers with heterogeneous clinical presentations (asymptomatic subjects, and ALS, ALS-
FTD and bvFTD patients). Based on the limited number of mutation carriers in our series, we think 
that the possible impact of genetic mutations on brain metabolism should be investigated in further 
studies including a larger amount of carriers. 
Another strength of this study is the contribution to the debate about the use of brain 18F-FDG-PET 




































































(EANM) and the European Academy of Neurology (EAN), did not recommend the clinical use of 
brain 18F-FDG-PET even to study ALS-related brain dysfunction [27,28]. We feel that the present 
data support the use of 18F-FDG-PET to study ALS-related brain changes across motor and 
cognitive regions in a research setting. Otherwise, in agreement with the EANM-EAN 
recommendations, its use in the clinical setting needs further studies, including the comparison with 
ALS-mimic disorders, to achieve a reliable accuracy at single patient level. 
To our knowledge, this is the first study evaluating the brain metabolic correlates of regional extent 
expressed as disease staging in ALS, and includes the largest ALS series with 18F-FDG-PET 
assessment ever published. We found that, with the increase of King’s stage, there was a decrease 
of metabolism in motor areas, with a progressive involvement of extramotor regions. Since 18F-
FDG-PET is a marker of neurodegeneration in vivo [10] and is considered valuable in cross-
sectionally evaluating the spread of lesions in ALS [29], our data are in keeping with the ALS 
neuropathological staging model supporting that neurodegeneration extends from the motor cortex 
to posterior and anterior regions, possibly via axonal pathways [3], and are in agreement with our 
population-based, cross-sectional data showing that cognitive impairment tends to be more severe 
as the clinical stage increases [14]. Longitudinal studies are indispensable for the correlation of 
brain metabolic alterations with the progressive clinical involvement of different body regions and 
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Figure 1  
Glass brain rendering of multiple regression of King’s stage against whole brain metabolism in the 
whole sample. The clusters showing a statistically significant negative correlation are projected on 
brain surface.  
 
Figure 2 
Glass brain rendering of the comparison: King’s stage 1+2 group versus King’s stage 3 group. The 
clusters showing a statistically significant relative hypometabolism in the King’s stage 3 group as 
compared to the King’s stage 1+2 group are projected on brain surface.  
 
Supplemental Figure 1 
Glass brain rendering of the full factorial analysis including the following groups: King’s stage 1, 
King’s stage, 2, King’s stage 3, and healthy controls. The clusters showing a significant main effect 
of groups are projected on brain surface. 
 
Supplemental Figure 2 
Glass brain rendering of the comparison: King’s stage 1 versus healthy controls. The clusters 
showing a statistically significant relative hypometabolism in the King’s stage 1 group as compared 
to healthy controls are projected on brain surface.  
 




































































Glass brain rendering of the comparison: King’s stage 2 versus healthy controls. The clusters 
showing a statistically significant relative hypometabolism in the King’s stage 2 group as compared 
to healthy controls are projected on brain surface.  
 
Supplemental Figure 4 
Glass brain rendering of the comparison: King’s stage 3 versus healthy controls. The clusters 
showing a statistically significant relative hypometabolism in the King’s stage 3 group as compared 















































































Table 1. Demographic and clinical characteristics of patients belonging to the three groups (King’s Stage 1, 2, and 3) and of the whole sample. Data 
about the presence/absence of genetic mutations were available for 369 out of 390 patients. The neuropsychological assessment was available for 
267 out of 390 patients: cognitive status was classified according to diagnostic criteria published by Strong et al. [13]  
 
 King’s Stage 
P value 
Total 
(n=390) 1 (n=165) 2 (n=133) 3 (n=92) 
Sex F (%) 
M (%) 
Total 
69 (41.8%) 58 (43.6%) 52 (56.5%) 
p=0.062 
179 (45.9%) 
96 (58.2%) 75 (56.4%) 40 (43.5%) 211 (54.1%) 
165 133 92 390 

































Site of Onset Bulbar (%) 58 (35.2%) 28 (21.1%) 41 (44.6%) 
p<0.001 
127 (32.6%) 
Spinal (%) 107 (64.8%) 105 (78.9%) 51 (55.4%) 263 (67.4%) 
Total 165 133 92 390 




































































Positive (%) 16 (9.9%) 13 (10.7%) 5 (5.8%) 34 (9.2%) 
Total 162 121 86 369 
SOD1 mutations Negative (%) 157 (96.9%) 119 (98.3%) 84 (97.7%) 
p=0.750 
360 (97.6%) 
Positive (%) 5 (3.1%) 2 (1.7%) 2 (2.3%) 9 (2.4%) 
Total 162 121 86 369 
TARDBP mutations Negative (%) 157 (96.9%) 117 (96.7%) 83 (96.5%) 
p=0.986 
357 (96.7%) 
Positive (%) 5 (3.1%) 4 (3.3%) 3 (3.5%) 12 (3.3%) 
Total 162 121 86 369 
FUS mutations Negative (%) 161 (99.4%) 118 (97.5%) 86 (100%) 
p=0.185 
365 (98.9%) 
Positive (%) 1 (0.6%) 3 (2.5%) 0 (0%) 4 (1.1%) 
Total 162 121 86 369 











Cognitive Status ALS-Cn (%) 70 (58.3%) 38 (44.7%) 26 (41.9%) 
p=0.019 
134 (50.2%) 
ALS-bi (%) 21 (17.5%) 22 (25.9%) 16 (25.8%) 59 (22.1%) 
ALS-ci (%) 16 (13.3%) 13 (15.3%) 3 (4.8%) 32 (12.0%) 
ALS-cbi (%) 7 (5.8%) 8 (9.4%) 7 (11.3%) 22 (8.2%) 
ALS-FTD (%) 6 (5.0%) 4 (4.7%) 10 (16.1%) 20 (7.5%) 





































































F: female. M: male. IQR: interquartile range. ALSFRS-R: ALS Functional Rating Scale – Revised. ALS-Cn: ALS with normal cognition. ALS-bi: 
ALS with behavioural impairment. ALS-ci: ALS with cognitive impairment. ALS-cbi: ALS with cognitive and behavioural impairment. ALS-FTD: 




































































Table 2. Results of the negative correlation between whole brain metabolism and King’s stage in 
the whole sample (BA=Brodmann Area). 
 
P (FWE-corr) Cluster Extent Z-score Talairach Coordinates Lobe Cortical Region BA 





































































































Table 3. Clusters showing a statistically significant relative hypometabolism in the King’s stage 3 
group as compared to the King’s stage 1+2 group (BA=Brodmann Area). 
 
p(FWE-corr) Cluster Extent Z-score Talairach Coordinates Lobe Cortical Region BA 
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